Incyte, Corp is an American pharmaceutical company based in Alapocas, Delaware. Incyte has one drug which has been approved by the U.S. Food and Drug Administration (FDA) and has been prescribed to several thousands of patients in the United States, Jakafi. The company was founded in Palo Alto, California in 1991 and went public in 1993. As of 2014 the company was developing an oral JAK1 and JAK2 inhibitor drug for rheumatoid arthritis in partnership with Eli Lilly called baricitinib. As of August 2016[update] 31 clinical trials had been registered for baricitinib of which 24 had completed, and 4 of 6 phase 3 trials had completed. As of 2016 epacadostat, an Indoleamine 2,3-dioxygenase (IDO1) inhibitor, is in development for various cancers. The ECHO-202 study (NCT02178722) is evaluating epacadostat in combination with Keytruda® (pembrolizumab)*, Merck’s anti-PD-1 therapy.
Highest paying job titles at Incyte include Oncology Specialist, Research Investigator, and Medical Director